- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Chronic plaque psoriasis Crohn’s disease Complex refractory fistulising Crohn’s disease Ulcerative colitis
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1576KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 292KB)
Infliximab – November 2020
Infliximab: Injection 120 mg in 1 mL pre-filled syringe, Injection 120 mg in 1 mL pre-filled pen: Remsima® SC
Last updated
6 July 2021